Abuse Potential of Morphine/ Dextromethorphan Combinations
|
|
- Harry Mills
- 5 years ago
- Views:
Transcription
1 S26 Journal of Pain and Symptom Management Vol. 19 No. 1(Suppl.) January 2000 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia Abuse Potential of Morphine/ Dextromethorphan Combinations Donald R. Jasinski, MD Clinical Studies/Center for Chemical Dependence, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA Abstract The potentiation of morphine analgesia by dextromethorphan raises the issue of whether dextromethorphan also potentiates those actions of morphine that lead to abuse. Clinical pharmacology experiments indicated that dextromethorphan does not potentiate the euphorigenic and miotic actions of morphine. Morphine suppresses the dysphoric action of dextromethorphan. A second set of experiments indicated that dextromethorphan does not alter the response to naloxone-precipitated withdrawal. In a third set of experiments, dextromethorphan did not alter the morphine-induced depression in the slope of the increase in minute volume in response to breathing increased CO 2. In contrast to potentiation of analgesia, dextromethorphan does not enhance the euphorigenic, physical dependence, and respiratory depressant actions of morphine. These findings indicate that dextromethorphan does not enhance the abuse potential of morphine and that the potentiation of analgesia appeared to be selective. J Pain Symptom Manage 2000;19:S26 S30. U.S. Cancer Pain Relief Committee, Key Words Abuse potential, euphoria, morphine/dextromethorphan, physical dependence capacity, respiratory depression capacity, selectivity Introduction Dextromethorphan is widely used as an overthe-counter antitussive that is recognized as effective and safe with little or no abuse potential. 1,2 Even though structurally related to drugs having opioid activity, dextromethorphan lacks morphine-like properties. In recent years, dextromethorphan has been investigated as an N-methyl-D-aspartate receptor antagonist. Preclinical experiments demonstrate that dextromethorphan reduces tolerance in Address reprint requests to: Donald R. Jasinski, MD, 4940 Eastern Avenue, Baltimore, MD Accepted for publication September 17, opiate-induced analgesia. In preclinical and clinical studies, dextromethorphan potentiates the analgesia of morphine and other opiates. Clinical studies show that potentiation of morphine by dextromethorphan is dose related. Studies indicate that this potentiation of morphine analgesia by dextromethorphan is not based on a pharmacokinetic interaction. An oral preparation, which combines morphine and dextromethorphan in a 1:1 weight ratio, is being introduced into therapeutics as an analgesic. In nondependent substance abusers, use of dextromethorphan in doses up to 240 mg orally and 240 mg sc indicated that dextromethorphan lacks the euphoric properties U.S. Cancer Pain Relief Committee, /00/$ see front matter Published by Elsevier, New York, New York PII S (99)00127-X
2 Vol. 19 No. 1(Suppl.) January 2000 Abuse of Morphine/Dextromethorphan S27 Fig. 1. Effect of dextromethorphan on the responses to morphine and placebo. In each graph, the squares represent the mean of the response on measures of euphoria to morphine and placebo in the presence of placebo. The circles represent the mean response to placebo and morphine in the presence of dextromethorphan. The error bars represent one-half the least significant difference as calculated from the error mean square and the analysis of variance. Statistical significance is indicated by lack of overlap of the error bars. of morphine. 3 Dextromethorphan is dysphoric, dilates pupils, and increases blood pressure. It does not produce morphine-like physical dependence. 4 However, the addition of dextromethorphan to morphine raises issues concerning the abuse liability of the combination. First, dextromethorphan could enhance the abuse liability of the combination by potentiating those actions of morphine that lead to diversion, abuse, and public health and social problems. Alternatively, the addition of dextromethorphan could decrease the abuse liability of morphine by adding a dysphoric component to the combination, thereby limiting the euphorigenic action. Clinical pharmacology studies were conducted to assess the abuse liability of the combination. In this context, abuse liability means the ability to be diverted, be abused, and create public health and social problems, including death, that occur with morphinelike drugs. Those pharmacological actions of morphine and other opiates responsible for this activity are: (1) the reinforcing or euphorigenic action of morphine as demonstrated in substance abusers; (2) the physical dependence capacity; and (3) the respiratory depressant capacity. Studies were conducted using clinical pharmacologic methods to assess abuse potential. 5 Study 1 The first study was a single-dose study conducted in 20 volunteer opiate abusers (17 male and 3 female). This was a double-blind crossover study in which drug combinations were administered at 48-h intervals in accordance with five 4 4 balanced Latin square design. Effects were measured predose and postdose at fixed intervals. In this study, four separate drug combinations were given orally to each subject. These were placebo/placebo, dextromethorphan 180 mg/placebo, placebo/morphine sulfate 180 mg, and dextromethorphan 180 mg/ morphine sulfate 180 mg. A 2 2 factorial design was utilized. It was assumed that 180 mg of oral morphine is equivalent to 30 mg of a parenteral dose of morphine. The dose of dextromethorphan was approximately 6 to 18 times the usual adult antitussive dose of 10 to 30 mg. In this study, dextromethorphan alone and morphine alone were active controls. Morphine produced the expected response, which
3 S28 Jasinski Vol. 19 No. 1(Suppl.) January 2000 Fig. 2. Effect of dextromethorphan on naloxone-precipitated withdrawal. Each response represents the mean area under the curve score, with the error bars representing one-half the least significant difference. Each square represents the mean response to withdrawal precipitated by naloxone in the presence of placebo and doses of dextromethorphan. Statistical significance is indicated by lack of overlap of the error bars. included constriction of pupils, increase on the liking scale and the Morphine Benzedrine Group (MBG) scale (measures of euphoria), (Fig. 1) and a slight increase in both supine and mean blood pressure readings. In contrast, dextromethorphan alone slightly dilated pupils, was not liked, produced no significant responses on either the liking or the MBG scale, and produced disliking (Fig. 1) and a slight increase in blood pressure and standing pulse. When the effects of the combination of morphine/dextromethorphan were compared to the effects of morphine alone, there was no greater effect on the euphorigenic measures of liking and MBG response. On the other hand, morphine reduced the dysphoric reaction, the pupillary dilatation, and the blood pressure effects of dextromethorphan. The significant findings of this study were that: (1) dextromethorphan does not potentiate the euphorigenic effects of morphine; (2) morphine suppresses the dysphoric effects of dextromethorphan; and (3) morphine suppresses the increases in pupil size, pulse, and blood pressure produced by dextromethorphan. It is therefore concluded that dextromethorphan neither enhances nor reduces the euphorigenic action of morphine. Study 2 The physical dependence capacity of an opiate can be demonstrated either through abrupt withdrawal of the opiate or by the administration of a competitive opiate antagonist such as naloxone. It is also known that short-term 24- to 36-h administration of morphine will result in the development of acute physical dependence. This can be seen when the administration of large doses of naloxone precipitates a withdrawal syndrome. Using this model, a second study was conducted in eight subjects in which the drug conditions were administered according to two 4 4 balanced Latin squares with a 1-day washout between experiments. Each experiment consisted of 2 days of drug administration. On the first day, each subject received morphine sulfate orally in a 60-mg dose at 6 AM, noon, 6 PM, and midnight. This was accompanied either by a dose of placebo or by a dose of dextromethorphan 30 mg, dextromethorphan 60 mg, or dextromethorphan 120 mg on each of the four occasions. At 6 AM on the second day, subjects received their original dose of dextromethorphan; at 6:30 AM, they were given morphine sulfate 30 mg im, and at 8:30 AM, naloxone was administered intramuscularly in a dose of 2.5 mg.
4 Vol. 19 No. 1(Suppl.) January 2000 Abuse of Morphine/Dextromethorphan S29 Fig. 3. Slope changes over time for the response of minute volume to increased CO 2. The squares represent the comparison of placebo to morphine in the presence of dextromethorphan/placebo at 0 h (predrug) and at 2, 4, and 6 h after dosing. The circles represent the response to morphine and placebo in the presence of dextromethorphan. Error bars represent one-half of the least significant difference. Statistical significance is indicated by lack of overlap of the error bars. Naloxone resulted in precipitated withdrawal as measured by a significant increase in pupil size, increases in tympanic temperature, pulse rate, and respiratory rate, and reports by both subjects and observers of withdrawal sickness. These effects lasted for about 1 h. The increasing doses of dextromethorphan had no significant effect on this acute precipitated withdrawal, as shown in Figure 2. Based on this study, it is concluded that dextromethorphan has no effect on naloxone-precipitated abstinence. This finding implies that dextromethorphan does not alter the physical dependence capacity of morphine. Study 3 The third clinical pharmacology study evaluated the effect of dextromethorphan on the respiratory depressive action of morphine. This study was conducted in 12 normal volunteers, defined as individuals without a history of opiate abuse. The study was a crossover, 2 2 factorial study in which four drug conditions were administered according to three 4 4 balanced Latin squares. Study drugs were given at 48-h intervals. The four drugs were: a placebo combination, morphine sulfate 60 mg alone, dextromethorphan 60 mg alone, and the combination of morphine sulfate 60 mg and dextromethorphan 60 mg. These doses represent the proposed therapeutic dose of the morphine/dextromethorphan combination. The procedure for assessing respiratory depression involved breathing fixed concentrations of carbon dioxide (CO 2 ): 2%, 4%, 6%, and 8% CO 2 in combination with 21% oxygen and the balance nitrogen. Subjects breathed from tanks for 2 min each, progressing from the lowest to the highest concentration. After each 2-min period, the subjects were allowed to breathe room air until they were comfortable; they then proceeded to the next CO 2 concentration. The minute volume was calculated from the last 15 breaths and was corrected for temperature, pressure, and water vapor. The measure of respiratory depression was the decrease in the slope of the minute volume/co 2 dose response curve. Morphine alone depressed the slope at the 2-, 4-, and 6-h postdrug observations, which can be seen in Figure 3. There was no evidence that dextromethorphan potentiated the decrease in the slope of the minute volume dose response curve more than morphine alone. On the basis of this study, it is concluded that dextromethorphan does not alter the respiratory depressant action of morphine. In summary, these three clinical pharmacology studies indicate that dextromethorphan does not alter the euphorigenic, physical de-
5 S30 Jasinski Vol. 19 No. 1(Suppl.) January 2000 pendence, or respiratory depressant capacities of morphine. These studies suggest that the potentiation of morphine analgesia by dextromethorphan is selective. Acknowledgment This research supported by a grant from Algos Pharmaceutical Corporation. References 1. Eddy NB, Friebel H, Hahn KJ, Halbach H. Codeine and its alternates for pain and cough relief. Bull World Health Org 1969;40: Bem JL, Peck R. Dextromethorphan: an overview of safety issues. Drug Safety 1992;7: Jasinski DR, Martin WR, Mansky PA. Progress report on the assessment of the antagonists nalbuphine and GPA-2087 for abuse potential and studies of the effects of dextromethorphan in man. Presented at 33rd Meeting, Committee on Problems of Drug Dependence, National Research Council; Toronto, Ontario, Canada, 1971b. 4. Isbell H, Fraser HF. Action and addiction liabilities of Dromoran derivatives in man. J Pharmacol Exp Ther 1953b;107: Jasinski DR. Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR, ed. Handbook of Experimental Pharmacology. 45/1, drug addiction I. Berlin, Heidelberg, New York: Springer-Verlag, 1977:
MorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationWR Fentanyl Symposium. Opioids, Overdose, and Fentanyls
Opioids, Overdose, and Fentanyls Outline: What are opioids? Why are we experiencing and opioid crisis? Potency, purity, and product How do opioids cause overdose and overdose deaths? What is naloxone and
More informationAnalgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I. Mr.D.Raju,M.pharm, Lecturer
Analgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I Mr.D.Raju,M.pharm, Lecturer Mechanisms of Pain and Nociception Nociception is the mechanism whereby noxious peripheral stimuli are transmitted to
More informationNMDA-Receptor Antagonists and Opioid Receptor Interactions as Related to Analgesia and Tolerance
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S7 Proceedings Supplement NDMA-Receptor Antagonists: Evolving Role in Analgesia NMDA-Receptor Antagonists and Opioid Receptor Interactions
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationDBL NALOXONE HYDROCHLORIDE INJECTION USP
Name of medicine Naloxone hydrochloride Data Sheet New Zealand DBL NALXNE HYDRCHLRIDE INJECTIN USP Presentation DBL Naloxone Hydrochloride Injection USP is a sterile, clear, colourless solution, free from
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationFentanyls and Naloxone. Opioids, Overdose, and Naloxone
Opioids, Overdose, and Naloxone Presenter Disclosure Presenter s Name: Michael Beazely I have no current or past relationships with commercial entities Speaking Fees for current program: I have received
More informationintravenous buprenorphine in humans
Subjective and physiologic effects of intravenous buprenorphine in humans The pharmacologic profile of sublingual and subcutaneous buprenorphine, a partial opioid agonist, indicates it may be useful as
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationReceptor Sites and Drug Design
Receptor Sites and Drug Design Case Study: piates use for Anesthesia & analgesia 1 PAI 2 The functional groups and their placement in three-dimensional space determines to a large degree a molecule s biological
More information6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages
Nalbuphine: Analgesic with a Niche Mellar P Davis MD FCCP FAAHPM 1 Summary of Advantages Safe in renal failure- fecal excretion Analgesia equal to morphine with fewer side effects Reduced constipation
More informationPAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)
Pain - subjective experience associated with detection of tissue damage ( nociception ) acute - serves as a warning chronic - nociception gone bad often accompanied by clinical depression fibromyalgia,
More informationAssessment of Opioid Partial Agonist Activity with a Three- Choice Hydromorphone Dose-Discrimination Procedure 1
0022-3565/99/2893-1350$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 289, No. 3 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationOpioids. Sergio Hernandez, MD
Opioids Sergio Hernandez, MD Required Slide Disclosures 1. SIGNIFICANT FINANCIAL INTERESTS NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT 2. GENERAL AND OBLIGATION INTERESTS All general
More information3/26/14. Opiates PSY B396 ALCOHOL, ALCOHOLISM, & DRUG ABUSE. Early History Cont d. Early History. Opiate Use in the 19th century. Technology Advances
Opiates PSY B396 ALCOHOL, ALCOHOLISM, & DRUG ABUSE Chapter 10 Opiates The most dramatic example of the doubleedged sword character of drugs Most potent painkillers Prototype addictive drug: Heroin Early
More informationA clinical trial of buprenorphine: Comparison with methadone in the
A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts The efficacy of buprenorphine and methadone was compared in the outpatient detoxification of heroin
More informationModule II Opioids 101 Opiate Opioid
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module II Opioids 101 Module II Goals of the Module This module reviews the following:! Opioid addiction and the brain!
More informationniap Terms and Definitions
Our topic today is about analgesics. niap General concept: pain brings patients to the Doctors at the same time. Fear from the pain can keep the patient from going to the Doctors at appropriate time. We
More informationWhat stronger oxycodone 15 or morphine ir 15
What stronger oxycodone 15 or morphine ir 15 Here's the problem. I'm on Oxycodone for break through pain, and MSContin for long term pain relief. The problem is Morphine makes me too tired. Posts about
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationTHE OPIUM POPPY OPIOID PHARMACOLOGY 2/18/16. PCTH 300/305 Andrew Horne, PhD MEDC 309. Papaver somniferum. Poppy Seeds Opiates
OPIOID PHARMACOLOGY PCTH 300/305 Andrew Horne, PhD andrew.horne@ubc.ca MEDC 309 THE OPIUM POPPY Papaver somniferum Sleep-bringing poppy Poppy Seeds Opiates Opium Poppy Straw 1 OPIATES VS. OPIOIDS Opiates:
More informationBIPHASIC ACTION OF PENTAZOCINE IN MORPHINE
BIPHASIC ACTION OF PENTAZOCINE IN MORPHINE DEPENDENT RATS Eijiro TAGASHIRA, Tomoko URANO, Tameo HIRAMORI and Saizo YANAU RA Department of Pharmacology. Hoshi College of Pharmacy, 2-4-41 Ebara, Shinagawa-ku,
More informationAn evaluation of the abuse potential of modafinil using methylphenidate as a reference
Journal of Psychopharmacology 14(1) (2000) 53 60 2000 British Association for Psychopharmacology (ISSN 0269-8811) SAGE Publications, London, Thousand Oaks, CA and New Delhi 0269 8811[200001]14:1; 53 60;
More informationRespiratory Effects of IV CR845 - A Peripherally Acting, Selective Kappa Opioid Receptor Agonist
Respiratory Effects of IV CR845 - A Peripherally Acting, Selective Kappa Opioid Receptor Agonist Eugene R. Viscusi, 1 Marc C. Torjman, 1 Joseph W. Stauffer, 2 Catherine L. Munera, 2 Beatrice S. Setnik,
More informationWhat is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls?
What is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls? What is an opioid? What do opioids do?: The term opioid can be
More informationA. Correct! Nociceptors are pain receptors stimulated by harmful stimuli, resulting in the sensation of pain.
Pharmacology - Problem Drill 19: Anti-Inflammatory and Analgesic Drugs No. 1 of 10 1. are pain receptors stimulated by harmful stimuli, resulting in the sensation of pain. #01 (A) Nociceptors (B) Histamines
More informationAgonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone
Opioid Definition All drugs, natural or synthetic, that bind to opiate receptors Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone Opioid agonists increase pain threshold
More informationTHE NALTREXONE CHALLENGE
THE NALTREXONE CHALLENGE DISCLOSURE Natasha Rodney-Cail, Pharmacist, Drug Evaluation Unit Has no conflicts of interest Maureen Allen Has no conflicts of interest DONNA 68 years old Currently treated with
More informationLESSON ASSIGNMENT. After completing this lesson, you should be able to: Given a group of definitions, select the definition of analgesia.
LESSON ASSIGNMENT LESSON 11 Narcotic Agents. LESSON ASSIGNMENT Paragraphs 11-1--11-7 LESSON OBJECTIVES After completing this lesson, you should be able to: 11-1. Given a group of definitions, select the
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationCase Study: Opiates use for Anesthesia & analgesia
rganic Lecture Series Receptor Sites and Drug Design Case Study: piates use for Anesthesia & analgesia 52 rganic Lecture Series PAI 53 Drug interactions at the cellular level rganic Lecture Series The
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationMethadone Maintenance
Methadone Maintenance A Practical Guide to Pharmacotherapy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Ron Joe, MD, DABAM Objectives I. Pharmacology Of Methadone II. Practical Application of Pharmacology
More informationDrug and Alcohol Dependence
Drug and Alcohol Dependence 105 (2009) 154 159 Contents lists available at ScienceDirect Drug and Alcohol Dependence journal homepage: www.elsevier.com/locate/drugalcdep Concurrent validation of the Clinical
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationAnnex II. Scientific conclusions. and detailed explanation of the scientific grounds for the differences. from the PRAC recommendation
Annex II Scientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 34 Scientific conclusions and detailed explanation of the scientific
More informationEffects of a Novel Fentanyl Derivative on Drug Discrimination and Learning in Rhesus Monkeys
PII S0091-3057(99)00058-1 Pharmacology Biochemistry and Behavior, Vol. 64, No. 2, pp. 367 371, 1999 1999 Elsevier Science Inc. Printed in the USA. All rights reserved 0091-3057/99/$ see front matter Effects
More informationHeroin. Brain Research Institute, UCLA Alison Taylor
Heroin Brain Research Institute, UCLA Alison Taylor Heroin H, Smack, Dope, Junk Can be purchased as a white powder White China or a dark resin Black Tar Opiates Derived from the opium poppy Morphine:
More informationClinical pharmacological aspects of heroin and fentanyl overdoses
Clinical pharmacological aspects of heroin and fentanyl overdoses Ola Dale Professor Norwegian University of Technology of Science St. Olav s University Hospital, Trondheim, Norway 1 Opioids Sydenham 1680:
More informationVOLUME C. Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations
VOLUME C Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations Module 2 Basics of opioid dependence Pharmacotherapy options Opioids: Definition, effects and treatment
More informationPRODUCT MONOGRAPH NALOXONE HYDROCHLORIDE INJECTION
PRODUCT MONOGRAPH Pr NALOXONE HYDROCHLORIDE INJECTION Naloxone Hydrochloride (as dihydrate) 0.4 mg/ml 1.0 mg/ml Omega Standard Therapeutic Classification Opioid Antagonist Omega Laboratories Limited Date
More informationDrugs Used In Management Of Pain. Dr. Aliah Alshanwani
Drugs Used In Management Of Pain Dr. Aliah Alshanwani 1 Drugs Used In Management Of Pain A CASE OF OVERDOSE Sigmund Freud, the father of psychoanalysis His cancer of the jaw was causing him increasingly
More informationAnalgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015
Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015 Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use
More informationOPIOIDS AND NON-CANCER PAIN
Ch05.qxd 1/6/04 4:33 PM Page 77 CHAPTER 5 OPIOIDS AND NON-CANCER PAIN Background 78 Side-effects of opioids 78 Tolerance, physical dependence and addiction 79 Opioid-induced pain 79 Practical issues 80
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More information12/14/2018. Disclosures. Buprenorphine. Drug-Receptor Interactions. Affinity
ECHO Ontario Chronic Pain Bootcamp OPIOID CHALLENGE Buprenorphine/Naloxone: What and How? Friday, December 7, 2018 Disclosures Presenters: John Flannery & Andrew Smith Conflicts of Interest: None John
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationOverdose Prevention and Management
Overdose Prevention and Management Programme Introduction to overdosing Programme Introduction to overdosing What does an overdose look like? Programme Introduction to overdosing What does an overdose
More informationInhibition of Cytochrome P450 2D6 Metabolism of Hydrocodone to Hydromorphone Does Not Importantly Affect Abuse Liability 1
0022-3565/97/2811-0103$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 281, No. 1 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationOverdose Treatment. Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine.
Part B 2 3 4 Overdose Treatment Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine. Specifically used to counteract lifethreatening depression of
More informationBuprenorphine Access in California
Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical
More informationon drug-induced euphoria and there is no reason why
Br. J. clin. Pharmac. (1978), 5, 299-33 DGR OF TOLRANC AND TH RLATIONSHIP BTWN PLASMA MORPHIN CONCNTRATION AND PUPIL DIAMTR FOLLOWING INTRAVNOUS HROIN IN MAN KATHLN H. TRSS & A.A. L-SOBKY Neuropsychology
More informationPRODUCT MONOGRAPH. Naloxone Hydrochloride. 0.4 mg/ml. Opioid Antagonist
PRODUCT MONOGRAPH Pr NALOXONE HYDROCHLORIDE INJECTION USP Naloxone Hydrochloride 0.4 mg/ml Opioid Antagonist Teligent OÜ Akadeemia tee 21/5 Tallinn, Estonia 12618 Date of Revision: August 25, 2016 Distributed
More informationPrevention of Development of Tolerance and Dependence to Opiate in Mice by BR-16A (Mentat) A Herbal Psychotropic Preparation
[Indian Journal of Experimental Biology (1992): (30), 885] Prevention of Development of Tolerance and Dependence to Opiate in Mice by BR-16A (Mentat) A Herbal Psychotropic Preparation Kulkarni, S.K. and
More informationDose-Response Analysis of Opioid Cross-Tolerance and Withdrawal Suppression During LAAM Maintenance 1
0022-3565/98/2852-0387$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 285, No. 2 Copyright 1998 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationSINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS OF MOXDUO, A DUAL-OPIOID FORMULATION CONTAINING A FIXED RATIO OF MORPHINE AND OXYCODONE
#298 SINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS OF MOXDUO, A DUAL-OPIOID FORMULATION CONTAINING A FIXED RATIO OF MORPHINE AND OXYCODONE LYNN WEBSTER, MD; 1 JOEL OWEN, PHD, RPH; 2 INGER DARLING, PHD;
More informationCare of the Dying: Is Pain Control Compromised or Enhanced by Continuation of the Fentanyl Transdermal Patch in the Dying Phase?
398 Journal of Pain and Symptom Management Vol. 24 No. 4 October 2002 Original Article Care of the Dying: Is Pain Control Compromised or Enhanced by Continuation of the Fentanyl Transdermal Patch in the
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationALVIMOPAN 0.0 OVERVIEW
ALVIMOPAN 0.0 OVERVIEW A. Alvimopan is a peripherally restricted mu-opioid receptor antagonist. B. DOSING INFORMATION : For the treatment of opioid bowel dysfunction, oral alvimopan doses between 0.5 milligrams
More informationDYNORPHIN-(1-13) SUPPRESSES HEROIN WITHDRAWAL SYMPTOMS IN 6 ADDICTS
DYNORPHIN-(1-13) SUPPRESSES HEROIN WITHDRAWAL SYMPTOMS IN 6 ADDICTS H.L. WEN (Neurosurgical Unit, Kwong Wah Hospital, Tung Wah Group of Hospitals, Kowloon, Hong Kong) P. Y. C. WEN (79 Hurlingham Court,
More informationClinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
Drug and Alcohol Dependence 70 (2003) S29/S37 Review Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? John Mendelson *, Reese T. Jones
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationAre codeine and dihydrocodeine the same
Home Search Are codeine and dihydrocodeine the same Dihydrocodeine is prescribed for moderate-to-severe types of pain. Learn more about the medication, including dosage and side effects, at Patient. 27-5-2010
More informationTHE OPIUM POPPY DERIVED FROM THE SAP OF OPIUM POPPIES. GROWN IN VARIOUS PARTS OF THE WORLD. SOUTHEAST & SOUTHWEST ASIA LATIN AMERICA MEXICO
COURSE OBJECTIVES OBJECTIVE 1: MAKING OBJECTIVE PRESUMPTIVE DIAGNOSES OF SUSPECTED OPIATE OVERDOSES. OBJECTIVE 2: PROPERLY ASSESS AND MANAGE A PATIENT EXPERIENCING A SUSPECTED OPIATE OVERDOSE. OBJECTIVE
More informationOtterbein Police Department. Opioid Addition Awareness
Otterbein Police Department Opioid Addition Awareness What are Opiates? Opioids are substances that act on opioid receptors to produce morphinelike effects. Medically they are primarily used for pain relief,
More informationInterprofessional Trauma Conference September 28th 2018 Montreal
Interprofessional Trauma Conference September 28th 2018 Montreal Marc Perreault & Marc Alexandre Duceppe ICU Pharmacists MGH & RVH-CUSM Faculté de Pharmacie Université de Montréal I have no potential conflict
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationNeuropharmacodynamic Profile of NKTR-181: Correlation to Low Abuse Potential
Neuropharmacodynamic Profile of NKTR-181: Correlation to Low Abuse Potential Laurie VanderVeen, Takahiro Miyazaki, Irene Choi, Michael A. Eldon, Xue Snow Ge, Hema Gursahani, Faye Hsieh, Aleksandrs Odinecs,
More informationHorizon Scanning Technology Briefing. Alvimopan (Entrareg ) for opioid-induced bowel disfunction. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Alvimopan (Entrareg ) for opioid-induced bowel disfunction August 2006 This technology briefing is based on information available at
More informationDr. Hiwa K. Saaed. PhD Pharmacology & Toxicology College of Pharmacy, University of Sulaimani Analgesic
12/17/18 Analgesics Opioids" Pharmacology Dr. Hiwa K. Saaed PhD Pharmacology & Toxicology College of Pharmacy, University of Sulaimani 2018-2019 1 Analgesic Analgesic an agent that selectively relieves
More informationBe courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off.
1 2 EMT OPTIONAL SKILL Naloxone Intranasal Cell Phones and Pagers Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off. 3 4 5 6 Course Outline Introduction
More informationAerobic and Anaerobic Respiration Revision 1
Aerobic and Anaerobic Respiration Revision 57 minutes 57 marks Page of 23 Q. An athlete did a 6-month training programme. The graph shows the effect of the same amount of exercise on his heart rate before
More informationThe Methadone Awareness Test*
The Methadone Awareness Test*!" #!$# # #%!&# %# #!! *The Methadone Awareness Test has been updated from the website. ' (!) %##% #! '! * ##" # ##! ' %#% %!% %#+%#%!,% %# #!, %%# %!'%%#%, %## % #!,% %!'
More informationImplementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018
Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018 Judith Martin, MD, Medical Director of Substance Use Services, San Francisco Department of Public Health Webinar
More informationThe effects of a new opioid analgesic, meptazinol, on the
Br. J. Pharmac. (1985), 85, 25-211 The effects of a new opioid analgesic, meptazinol, on the respiration of the conscious rat I.S. Cowlrick' & N.B. Shepperson2 Wyeth Laboratories, Huntercombe Lane South,
More informationOxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.
Page 1 of 7 Policies Repository Policy Title Policy Number Schedule II Prior Authorization FS.CLIN.16 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on
More informationNaloxone Intranasal EMT OPTIONAL SKILL. Cell Phones and Pagers. Course Outline 09/2017
EMT OPTIONAL SKILL Naloxone Intranasal Cell Phones and Pagers Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off. Course Outline Introduction and Overview
More informationPAIN. Physiology of pain relating to pain management
PAIN Physiology of pain relating to pain management What is pain? An unpleasant sensory and emotional experience associated with actual or potential tissue damage. (Melzac and Wall) The generation of pain
More informationIdeal Sedative Agent. Pharmacokinetics. Benzodiazepines. Pharmacodynamics 11/11/2013
Ideal Sedative Agent Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry Peter Walker Anxiolysis Analgesic No effect on CVS No effect on respiratory system Not metabolised Easy and
More informationSustained-release preparations of naltrexone for the treatment of alcohol and opioid dependence: current status
Sustained-release preparations of naltrexone for the treatment of alcohol and opioid dependence: current status Linda R. Gowing, Discipline of Pharmacology, University of Adelaide Sarah Larney, National
More informationIdeal Sedative Agent. Benzodiazepines 11/12/2013. Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry.
Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry Peter Walker Ideal Sedative Agent Anxiolysis Analgesic No effect on CVS No effect on respiratory system Not metabolised Easy and
More informationPK/PD analysis in assessment of abuse deterrence
PK/PD analysis in assessment of abuse deterrence Megan J. Shram, PhD Director and Principal, Altreos Research Partners Inc. Adjunct Professor and Lecturer, Department of Pharmacology, University of Toronto
More informationClinical Trial Results with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S25 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationWill oxycodone 5mg hurt a dog
P ford residence southampton, ny Will oxycodone 5mg hurt a dog 17-3-2012 How much oxycodone is too much. I figured i was taking 50 MG of oxy a day so it wouldn't hurt. I have a couple of oxycodone 5 mg
More informationBrief Pain Surveys. Developed by: Betty R. Ferrell, PhD, FAAN and Margo McCaffery RN, MSN, FAAN
Brief Pain Surveys Pain Assessment/Behavior Survey Pain/Gender Survey Brief Cancer Pain Information Survey Pain Addiction Survey Brief Pharmacology Survey Test Questions Developed by: Betty R. Ferrell,
More informationPain is a more terrible Lord of mankind than even death itself.
CHRONIC OPIOID RX FOR NON-MALIGNANT PAIN Gerald M. Aronoff, M.D., DABPM Med. Dir., Carolina Pain Assoc Charlotte, North Carolina, USA Pain Pain is a more terrible Lord of mankind than even death itself.
More informationOpioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory
Opioids: Use, Abuse and Cause of Death Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory jharmon@occl.ocgov.com Opioid: Any psychoactive chemical that resembles morphine
More informationDextromethorphan Attenuates Ethanol Withdrawal Syndrome in Rats
PII S0091-3057(98)00175-0 Pharmacology Biochemistry and Behavior, Vol. 62, No. 3, pp. 537 541, 1999 1999 Elsevier Science Inc. Printed in the USA. All rights reserved 0091-3057/99 $ see front matter Dextromethorphan
More informationOverview of Pharmacodynamics. Psyc 472 Pharmacology of Psychoactive Drugs. Pharmacodynamics. Effects on Target Binding Site.
Pharmacodynamics Overview of Pharmacodynamics Psychology 472: Pharmacology of Psychoactive Drugs Generally is defined as effects of drugs on a systems Can be associated with any system Neural, Heart, Liver,
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationThe Reinforcing and Subjective Effects of Morphine in Post- Addicts: A Dose-Response Study
22-3565/91/2593-1 165$./ THE JOURAL OF PHARMACOLOGY AD EXPERIMETAL THERAPEUTICS Copyright C 1991 by The American Society for Pharmacology and Experimental Therapeutics ol. 259, o. 3 Printed in USA. The
More informationIntravenous Dezocine for Postoperative Pain: A Double-Blind, Placebo-Controlled Comparison With Morphine
Intravenous for Postoperative Pain: A Double-Blind, Placebo-Controlled Comparison With Morphine Uma A. Pandit, MD, S aria P. Kothary, MD, and Sujit K. Pandit, MD, PhD, a new mixed agonist-antagonist opioid
More informationDr Alistair Dunn. General Practitioner Whangarei
Dr Alistair Dunn General Practitioner Whangarei 1982 Temgesic = Buprenorphine Sublingual opiate analgesic 0.2 mg Popular drug of abuse 1991 Temgesic NX = Bup & Nalxone Nalxone added to deter abuse 1999
More informationOpioid Harm Reduction
Opioid Harm Reduction Lucas G. Hill, PharmD Clinical Assistant Professor, The University of Texas at Austin College of Pharmacy Clinical Pharmacist, CommUnityCare FQHCs Director, Operation Naloxone Mark
More informationMEDICAL ADVISORY COUNCIL Position Statement PREHOSPITAL PAIN MANAGEMENT
MEDICAL ADVISORY COUNCIL Position Statement PREHOSPITAL PAIN MANAGEMENT MAC PS 2013-002 Appropriate treatment of acute pain in the prehospital arena offers an opportunity to positively impact many patients.
More information3. IC50 represents the concentration of antagonist needed to displace the ligand from 50% of the available receptors.
Paper 2 True False Ouestions ~ 1. Tubocurarine is a nicotinic receptor antagonist. 2. In a dose-response curve ED50 represents the dose which elicits 50% of the maximal response and Emax represents the
More information